Clinical trials: Cancer Therapy-Related Cardiac Dysfunction
Heart Failure, Cancer, Therapy-Related
Identification of Anticancer Drugs Associated With Cancer Therapy-related Cardiac Dysfunction: a Pharmacovigilance Study
Therapeutic advances have significantly improved the survival of patients with cancer. However, these novel therapies are associated with a concomitant increase in the prevalence of toxicity, including cardiovascular…
- Trial name
- NCT06268535
- Testing
- Cancer therapy with FDA and/or European Medicines Agency approval on the 30th September 2023
- Where
- France
- Volunteers
- 36,580,288 people
- Sponsor
- University Hospital, Caen
Cancer Therapy-Related Cardiac Dysfunction, Cardio-oncology
Structured Cardio-Oncology Rehabilitation for Cardiovascular Outcomes in Cancer Survivors
Cancer therapy-related cardiac dysfunction (CTRCD) has become a major cause of morbidity and mortality among cancer survivors. Although cardiac rehabilitation is recommended for cardiovascular disease prevention and management…
- Conditions
- Cancer Therapy-Related Cardiac Dysfunction, Cardio-oncology, Cancer Survivorship, Cardiovascular Risk
- Trial name
- CORE-CTRCD (NCT07622394)
- Testing
- Structured Cardio-Oncology Rehabilitation, Usual Care
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Xinjiang Medical University
Malignancies, Cardiovascular Diseases
Cancer Therapy-related Cardiac Dysfunction Occuring in Children Treated by Anticancer Drugs for Malignancies
Little is known about cancer therapy-related cardiac dysfunction occuring in children treated by anticancer drugs for malignancies.
- Conditions
- Malignancies, Cardiovascular Diseases, Children, Only
- Trial name
- NCT05602103
- Testing
- use of anticancer drugs in monotherapy or in combination therapy
- Volunteers
- 10,000 people
- Sponsor
- University Hospital, Caen